

The Oncomine Dx Express Test for oncology biomarker profiling

A patient's tumor profile has the potential to guide precision oncology care, but only if the results are reported in time. Now, with the Ion Torrent™ Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx System*, you can perform fast NGS testing for clinically relevant biomarkers in as little as 24 hours.



EGFR

The time to informed treatment decisions is critical for oncology patients



<24

as little as 24 hours
turnaround time from
sample to clinically
relevant biomarker report

KRAS



Patients everywhere should be routinely tested for clinically relevant biomarkers

46 genes

including *EGFR*, *ALK*, *BRAF*, *ROS1*, *RET*, *KRAS*, *PIK3CA*, *NTRK*, *MET*, *IDH1* and *ERBB2*, among others

100%

clinically relevant biomarkers for NSCLC and majority for other solid tumors^{1,2}

¹100% clinically relevant biomarkers – unique biomarkers that have an ESCAT level of IA, IB, or IC; majority = 86%, *BRAF*1/2 and *MSI-H* are not covered by the Oncomine Dx Express Test.

²Mosele F. et al. (2020) *Ann Oncol* 31:1491

Even small biopsies should generate results

10 ng

minimum
sample input



~95%

sample
success rate



RET

Automation and ease of use are key to enabling implementation of NGS workflows in every laboratory

2




instruments*

1

software and report linking biomarkers with relevant evidence from approved therapies, guidelines, and clinical trials



2



touchpoints

20

minutes hands-on time



1



supplier and team to support you

ROS1



* The content provided herein may relate to products or workflows that have not been officially released or fully validated and is subject to change without notice.